Okyo registers Phase 3 trial of urcosimod for neuropathic corneal painSep 24Trial updateOkyo Pharma Ltdurcosimod
Okyo Pharma to present at two European ophthalmology industry events in September 2026Sep 9Clinical readoutOkyo Pharma Ltdurcosimod
OKYO Pharma gets FDA Type D feedback, moves urcosimod into global Phase 3 for eye painJul 8Clinical readoutOkyo Pharma Ltdurcosimod
Sign inSign in